Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose iloprost power 15 vs placebo on exercise capacity in pulmonary arterial hypertension
2009-010703-80Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iloprost in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Apr 2009; status: completed.
02
Drugs
iloprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2009-010703-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010703-80.